Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NKTR logo NKTR
Upturn stock ratingUpturn stock rating
NKTR logo

Nektar Therapeutics (NKTR)

Upturn stock ratingUpturn stock rating
$24.76
Last Close (24-hour delay)
Profit since last BUY-16.58%
upturn advisory
Consider higher Upturn Star rating
BUY since 6 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: NKTR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $96.8

1 Year Target Price $96.8

Analysts Price Target For last 52 week
$96.8 Target price
52w Low $6.48
Current$24.76
52w High $37.38

Analysis of Past Performance

Type Stock
Historic Profit -6.95%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 307.19M USD
Price to earnings Ratio -
1Y Target Price 96.8
Price to earnings Ratio -
1Y Target Price 96.8
Volume (30-day avg) 8
Beta 0.56
52 Weeks Range 6.48 - 37.38
Updated Date 07/4/2025
52 Weeks Range 6.48 - 37.38
Updated Date 07/4/2025
Dividends yield (FY) -
Basic EPS (TTM) -9.45

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -152.49%
Operating Margin (TTM) -424.15%

Management Effectiveness

Return on Assets (TTM) -26.8%
Return on Equity (TTM) -189.46%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 188899967
Price to Sales(TTM) 3.52
Enterprise Value 188899967
Price to Sales(TTM) 3.52
Enterprise Value to Revenue 2.17
Enterprise Value to EBITDA -6.5
Shares Outstanding 12406900
Shares Floating 12233960
Shares Outstanding 12406900
Shares Floating 12233960
Percent Insiders 1.29
Percent Institutions 67.11

ai summary icon Upturn AI SWOT

Nektar Therapeutics

stock logo

Company Overview

overview logo History and Background

Nektar Therapeutics, founded in 1990, is a biopharmaceutical company focusing on discovering and developing innovative medicines using its proprietary PEGylation and advanced polymer conjugate technologies. Initially focused on drug delivery, it has evolved into developing its own pipeline of immuno-oncology assets.

business area logo Core Business Areas

  • Research and Development: Discovery and development of new drug candidates, primarily in immuno-oncology.
  • Manufacturing: Production of PEGylation reagents and certain drug candidates for clinical trials and potential commercialization.

leadership logo Leadership and Structure

Nektar's leadership team consists of seasoned pharmaceutical executives with expertise in drug development, commercialization, and finance. The company operates with a functional organizational structure, with departments dedicated to R&D, manufacturing, clinical development, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • NKTR-255: A novel IL-15 receptor agonist being developed for various cancer indications. It is in clinical trials. There are many IL-15 agonist/fusion protein that are being developed, including ALT-803 from Altor BioScience, and RO7297089 from Roche
  • REZPEG (Baxdrostat): Originally licensed to Roche, this drug was aimed at treating uncontrolled hypertension, but Roche returned the rights to Nektar in late 2023 after failing to demonstrate efficacy in phase 3 trials.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Immuno-oncology is a rapidly growing segment within the industry, driven by advances in understanding the role of the immune system in cancer.

Positioning

Nektar Therapeutics focuses on utilizing its polymer conjugation technologies to develop novel immuno-oncology therapies. Its competitive advantage lies in its ability to create differentiated drug candidates with improved efficacy and safety profiles.

Total Addressable Market (TAM)

The global immuno-oncology market is projected to reach hundreds of billions of USD. Nektar is positioned to capture a portion of this TAM with successful development and commercialization of its pipeline assets.

Upturn SWOT Analysis

Strengths

  • Proprietary PEGylation and polymer conjugation technologies
  • Experienced management team
  • Focus on immuno-oncology, a high-growth area
  • Potentially differentiated drug candidates

Weaknesses

  • Reliance on successful clinical trial outcomes
  • High cash burn rate
  • Competition from larger pharmaceutical companies
  • History of clinical trial failures

Opportunities

  • Potential partnerships with larger pharmaceutical companies
  • Expansion of pipeline through internal R&D and acquisitions
  • Positive clinical trial results for lead drug candidates
  • Growing demand for innovative cancer therapies

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other immuno-oncology therapies
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • MRK
  • PFE
  • AZN
  • RHHBY

Competitive Landscape

Nektar faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Nektar differentiates itself through its proprietary technology and focus on novel immuno-oncology targets.

Growth Trajectory and Initiatives

Historical Growth: Data not available in the context to provide specific historical growth data.

Future Projections: Future growth is dependent on successful clinical trials and commercialization of its pipeline assets. Analyst estimates vary significantly.

Recent Initiatives: Recent initiatives include focusing on its lead immuno-oncology programs and seeking strategic partnerships.

Summary

Nektar Therapeutics is a biopharmaceutical company with a focus on immuno-oncology, leveraging its proprietary PEGylation technology. The company's success hinges on the clinical trial outcomes of its lead drug candidates, particularly NKTR-255. It faces substantial risks due to high cash burn and competition from larger pharmaceutical players. Positive clinical data and strategic partnerships are crucial for its future growth, with focus on early-stage clinical assets.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nektar Therapeutics

Exchange NASDAQ
Headquaters San Francisco, CA, United States
IPO Launch date 1994-05-03
CEO, President & Director Mr. Howard W. Robin
Sector Healthcare
Industry Biotechnology
Full time employees 61
Full time employees 61

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.